Research programme: withanolide compounds - ImStar Therapeutics

Drug Profile

Research programme: withanolide compounds - ImStar Therapeutics

Alternative Names: IMS-088; Novel Withanolides - Imstar Therapeutics

Latest Information Update: 29 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImStar Therapeutics
  • Class Radiation-sensitising agents; Small molecules; Withanolides
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 26 Nov 2013 Preclinical trials in Amyotrophic lateral sclerosis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top